Treatment-Free Remission for Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #CML-603; Location: LEVEL 3, HALL B3; "Frontline TKI was started 0.51 months (0.03–240.39 months) after diagnosis: imatinib in 17 patients (47.22%), dasatinib in 11 (30.56%), nilotinib in 7 (19.44%), and ponatinib in 1 (2.78%). These preliminary results demonstrate the feasibility of TFR strategies, including in patients with AP-CML at diagnosis. AP-CML: accelerated phase chronic myeloid leukemia, BCR::ABL1: breakpoint cluster region–Abelson 1, BM: bone marrow, CE: clonal evolution, CML: chronic myeloid leukemia, CP: chronic phase, DMR: deep molecular response, ELN: European LeukemiaNet, MMR: major molecular response, MR: molecular response, MRFS: molecular relapse-free survival, PB: peripheral blood, TKI: tyrosine kinase inhibitor, TFR: treatment-free remission."
Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Fadi G Haddad MD 1; Gabriel Etienne MD PhD 2; Yoann Grimaud MD 3; Julien Bollard PhD 3; Julie Hildt BSc 3; Christophe Bouvier MSc 3; François-Xavier Mahon MD PhD 2; Sara Dellasala MSc 1; Stéphane Morisset MSc 3; Ghayas C Issa MD 1; Elias Jabbour MD 1; Hagop M Kantarjian MD 1; Franck E Nicolini MD PhD 3
|